
Venetoclax Retreatment and Post-BTK Inhibitor Choices in CLL
The panelists discussed the role of venetoclax-based therapy in relapsed chronic lymphocytic leukemia (CLL), including venetoclax-rituximab as a time-limited standard supported by long-term survival data, while noting that few patients in its pivotal trial had received a prior Bruton tyrosine kinase (BTK) inhibitor.
Episodes in this series

The panelists discussed the role of venetoclax-based therapy in relapsed chronic lymphocytic leukemia (CLL), including venetoclax-rituximab as a time-limited standard supported by long-term survival data, while noting that few patients in its pivotal trial had received a prior Bruton tyrosine kinase (BTK) inhibitor. They reviewed venetoclax monotherapy and emerging retreatment evidence and described retreatment as attractive after a prolonged remission off venetoclax. They also considered cytogenetic risk, the reason a prior BTK inhibitor was stopped, tumor lysis risk, ramp-up visits, and distance from the clinic when making treatment decisions. The panelists then discussed how they choose after progression on a covalent BTK inhibitor, weighing simple, once-daily oral pirtobrutinib against time-limited venetoclax with rituximab or obinutuzumab, which has longer follow-up. They emphasized patient preference and noted that bulky adenopathy or renal impairment may favor pirtobrutinib, whereas cardiovascular issues with low disease burden and normal renal function may favor venetoclax-based treatment.
Related to this article







